Shots:

• Amgen receives in-favor upholding validity for Repatha from Delaware Jury- with two out of five asserted claims based on its patents meeting the legal requirements of written description and enablement
• In Mar-2016 Sanofi and Regeneron admitted infringement of Amgen's patents- regaining Amgen with two patents of Repatha but was overturned on appeal in the US District Court for the District of Delaware
• Sanofi and Regeneron plans to file appeal to the Court of Appeals- in addition to the District Court for overturning the jury’s verdict with the onset of new trial 
• Repatha (evolocumab) is mAb inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and is approved in 60 countries including the US- Japan- Canada & EU

Ref: Amgen | Image: Twitter